Multi-Modal Longevity Protocol Including Autologous Cell-Free Conditioned Media

December 22, 2025 updated by: BlueBird Age Reversal SA

A Multi-Modal Longevity Protocol Integrating Lifestyle, Supplements, and Autologous Pro-Regenerative Cell-Conditioned Media: A Pilot Study

This pilot study evaluated a multi-modal longevity protocol combining lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media derived from peripheral blood-derived pro-regenerative cells (APRC-CM). Fourteen healthy adult participants completed a 17-week programme including baseline and post-intervention biomarker assessments. The primary objective was to characterise changes in biological age using DNA methylation-based epigenetic clocks, PhenoAge and other physiological and biochemical markers.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This exploratory study investigated the biological effects of a structured, multi-modal longevity programme that included lifestyle optimisation (nutrition, exercise, sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells cultured ex vivo to produce a pro-regenerative secretome containing soluble factors and extracellular vesicles.

Participants underwent biomarker assessments at baseline and at week 17. Outcomes included measurements of epigenetic biological age, phenotypic age, inflammatory markers, metabolic markers, and other laboratory and physiological variables. The study was conducted in healthy adults and designed as a minimal-risk physiological investigation.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • London, United Kingdom, W1G 0PG
        • Wellbeing International Foundation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age 45 years or older
  • Generally good overall health as assessed by the study team
  • Able and willing to provide written informed consent
  • Willing to participate in all components of the study protocol, including lifestyle optimisation, nutritional supplementation, blood collection, and scheduled follow-up visits
  • Able to comply with study procedures for the duration of the intervention and assessments

Exclusion Criteria:

  • Presence of a major medical condition that, in the opinion of the investigators, could affect participation or safety
  • Any condition requiring hospitalization or emergency medical intervention within the past 12 months
  • Receipt of anti-aging or longevity treatments within the past six months (e.g., intravenous therapies, regenerative or cellular treatments, structured age-reversal programmes)
  • Active infectious disease at enrolment
  • Pregnancy or breastfeeding
  • Use of systemic immunomodulatory, cytotoxic, or investigational treatments in the prior 3 months
  • Any condition or circumstance that, in the judgement of the investigators, may interfere with study participation or data integrity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Longevity Protocol Arm
Participants received a structured, multi-modal longevity protocol consisting of lifestyle optimization, nutritional supplementation, and autologous cell-free conditioned media (APRC-CM) prepared individually from peripheral blood-derived pro-regenerative cells. All participants received the same intervention schedule over a 17-week period.
Behavioral: Multi-Modal Longevity Protocol
The intervention consisted of a structured, multi-modal longevity program that included lifestyle optimization (nutrition, physical activity, and sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells and administered as part of a physiologic, minimal-risk exploratory protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Epigenetic Biological Age
Time Frame: Baseline and Week 17
Biological age calculated from DNA methylation profiles using validated epigenetic clock algorithms.
Baseline and Week 17

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Phenotypic Age
Time Frame: Baseline and Week 17
Phenotypic age calculated from clinical biomarkers using published phenotypic age algorithms.
Baseline and Week 17

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Adverse Events
Time Frame: From baseline to Week 17
Monitoring of any self-reported or observed adverse events throughout the study period. Events were recorded and assessed descriptively.
From baseline to Week 17

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

BlueBird Age Reversal SA

Collaborators

xLongevity
Wellbeing International Foundation

Investigators

  • Principal Investigator: Esteban Ortega, MD, Wellbeing International Foundation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 5, 2024

Primary Completion (Actual)

December 15, 2024

Study Completion (Actual)

March 20, 2025

Study Registration Dates

First Submitted

December 5, 2025

First Submitted That Met QC Criteria

December 22, 2025

First Posted (Actual)

January 7, 2026

Study Record Updates

Last Update Posted (Actual)

January 7, 2026

Last Update Submitted That Met QC Criteria

December 22, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • BB-ART3-2024-PILOT

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared because the dataset includes biological, clinical, and demographic information that may be potentially identifiable, and no data-sharing agreements or infrastructure were established for this pilot study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Aging

Clinical Trials on Multi-Modal Longevity Protocol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe